Last reviewed · How we verify
Gary A Levy, O. Ont. MD. FRCP AGAF — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams Maternity Hospital · 1 shared drug class
- Gwo Xi Stem Cell Applied Technology Co., Ltd. · 1 shared drug class
- Manipal Acunova Ltd. · 1 shared drug class
- Mesoblast, Inc. · 1 shared drug class
- Nature Cell Co. Ltd. · 1 shared drug class
- Tigenix S.A.U. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Gary A Levy, O. Ont. MD. FRCP AGAF:
- Gary A Levy, O. Ont. MD. FRCP AGAF pipeline updates — RSS
- Gary A Levy, O. Ont. MD. FRCP AGAF pipeline updates — Atom
- Gary A Levy, O. Ont. MD. FRCP AGAF pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Gary A Levy, O. Ont. MD. FRCP AGAF — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gary-a-levy-o-ont-md-frcp-agaf. Accessed 2026-05-17.